<acronym id="o0b7z"><label id="o0b7z"></label></acronym>

        <td id="o0b7z"><center id="o0b7z"><ol id="o0b7z"></ol></center></td><table id="o0b7z"><strike id="o0b7z"></strike></table>

        1. About Us
        2. Our Team
        3. Our Mission And Values
        4. Social Responsibility

        5

        Zelgen has been granted with five National Major Scientific Funds

        70

        More than 70 patents have been issued in USA, EU, China and other countries.


        130

        The company has filed about 130 patent applications in worldwide


        Founded in 2009, Suzhou Zelgen Biopharmaceuticals Co., Ltd. ( Ticker 688266) is located in the Kunshan National New & High-tech District (KSND) in Jiangsu Province, China. This is a joint venture established by Chinese and American pharmaceutical experts, forming the company from four subsidiaries, US Gensun Biopharma Inc., Shanghai Zelgen Pharma-Tech Co. Ltd., Suzhou Zelgen Biosciences Co. Ltd., and Zelgen Holdings Ltd. Suzhou Zelgen Biopharmaceuticals, specializes in the research and development (R&D), manufacturing, and distribution of innovative medicines. Our goal is to become the leading pharmaceutical company in China focusing on the areas of oncology, hematology,gastroenterology and inflammatory-immune diseases. The company's market strategy emphasizes China, while expanding business opportunities internationally. Our mission is to develop innovative drugs for unmet therapeutic markets that are safe, effective, affordable, and for which we have intellectual property ownership.


        The maintenance of a robust, proprietary pipeline is crucial to our business. To successfully meet this goal, Zelgen has successfully established two cutting-edge technology platforms, the R&D platform and commercialized platform, for the discovery and development of both small molecule and recombinant protein drugs. This has enabled us to build-up a strong pipeline covering treatment areas including liver cancer, non-small cell lung cancer, colorectal cancer, thyroid cancer, nasopharyngeal carcinomas, myelofibrosis, hemorrhage, and hepatobiliary diseases. Zelgen is also working together with several other Chinese pharmaceutical companies to co-develop combination treatments of targeted small molecule drugs and anti-PD-1/PD-L1 antibodies.


        Zelgens programs have been funded five-times with awards from the National Major Innovation Drugs Fund, the National Innovation Fund for Small Technology Company, as well as other provincial Science and Technology Funds. The company has filed over 130 patent applications worldwide, and more than 70 patents have been issued in USA, EU, China and other countries.


        The Company has three R&D centers located in Kunshan, Shanghai Zhangjiang Drug Valley, and California, USA.


        Zelgen has built two manufacturing facilities in compliance with cGMP guidance in Kunshan, one for tablets/capsules of small molecule drugs and another for protein drugs. These facilities ensure that Zelgen has more flexible manufacturing capacity, effective cost-control, and competitive advantages.









         about-82414


        一级特黄aa大片毛日本,我不卡影院午夜伦不卡,五月天婷五月天综合网,午夜福利2020国产最新在线观看
        <acronym id="o0b7z"><label id="o0b7z"></label></acronym>

            <td id="o0b7z"><center id="o0b7z"><ol id="o0b7z"></ol></center></td><table id="o0b7z"><strike id="o0b7z"></strike></table>